Millions are affected by lung conditions, often unaware of risks. Asthma + Lung UK's Andy Whittamore shares tips for ...

Patients with bronchiectasis in China have a high disease burden and a low rate of use of evidence-based treatments.

Though asthma-related ER visits have dropped, advocates still worry about industry's impact on health. Could new Allegheny County leadership spell change?

The FDA has granted priority review to brensocatib to treat patients with non-cystic fibrosis bronchiectasis, according to a ...

Background Early-life inflammation has long been recognised as a key pathophysiological process in the evolution of cystic ...

Insmed's promising drug pipeline includes Brensocatib and Arikayce. See why INSM stock is a strong pick with multi-billion ...

The FDA accepts and grants priority review to INSM's NDA for brensocatib to treat patients with non-cystic fibrosis bronchiectasis. A decision is due on Aug. 12, 2025.

The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for ...

BRIDGEWATER, N.J. - Insmed Incorporated (NASDAQ:INSM), a biopharmaceutical company with a market capitalization of $14.57 ...

The Bridgewater, N.J., biopharmaceutical company said brensocatib has the potential to become the first and only approved treatment for non-cystic fibrosis bronchiectasis, which causes the lungs' ...

In a significant recognition of her remarkable contributions to the field of paediatric lung health, Professor Refiloe ...

In a report released today, Roy Buchanan from JMP Securities maintained a Buy rating on AN2 Therapeutics, Inc. (ANTX – Research Report), with a ...